^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCL12 expression

    i
    Other names: CXCL12, C-X-C Motif Chemokine Ligand 12, Stromal Cell-Derived Factor 1, PBSF, Pre-B Cell Growth-Stimulating Factor, Chemokine (C-X-C Motif) Ligand 12, Intercrine Reduced In Hepatomas, SCYB12, TPAR1, SDF1, IRH, C-X-C Motif Chemokine 12, CXCL12, SDF-1a, SDF-1b, TLSF-A, TLSF-B, HSDF-1, SDF1A, SDF1B, SDF-1, TLSF, HIRH
    Entrez ID:
    6387
    Related biomarkers:
    Expression
    Mutation
    Others
    2ms
    Key Genes Involved in the Beneficial Mechanism of Hyperbaric Oxygen for Glioblastoma and Predictive Indicators of Hyperbaric Oxygen Prolonging Survival in Glioblastoma Patients. (PubMed, Curr Med Sci)
    HBO is beneficial for glioblastoma. Glioblastoma patients with these predictive indicators may prolong survival with HBO therapy. These potential therapeutic targets especially COL1A1, ADAMTS1 and PTBP3 deserve further validation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PD-1 (Programmed cell death 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • MDM4 (The mouse double minute 4) • CDK6 (Cyclin-dependent kinase 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CA9 (Carbonic anhydrase 9) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1) • CDC42 (Cell Division Cycle 42) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • DDIT3 (DNA-damage-inducible transcript 3) • IGFBP3 (Insulin-like growth factor binding protein 3) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5) • BAK1 (BCL2 Antagonist/Killer 1) • CDC25A (Cell Division Cycle 25A) • COL12A1 (Collagen Type XII Alpha 1 Chain) • COL8A1 (Collagen Type VIII Alpha 1 Chain) • EFEMP1 (EGF Containing Fibulin Extracellular Matrix Protein 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MCM2 (Minichromosome maintenance complex component 2) • RHOJ (Ras Homolog Family Member J) • NLRP2 (NLR Family Pyrin Domain Containing 2)
    |
    TP53 expression • CXCL12 expression • CDK6 expression • CDKN1B expression • PCNA expression
    2ms
    The Effect of C-X-C Motif Chemokine Ligand 12 in Colorectal Cancer Associated with Chemoresistance and Radioresistance as Well as Stemness. (PubMed, Iran J Public Health)
    In addition, the chemosensitivity and radiotherapy tolerance were elevated after transfected with CXCL12. CXCL12 could be a potential promote biomarkers in CRC and also promote the chemosensitivity and radiotherapy tolerance.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    2ms
    Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma. (PubMed, J Transl Med)
    The TEC score is a promising and reliable biomarker for predicting genetic mutations and prognosis in ICC patients. Enhancing the regulation of the CXCL12/CXCR4 signaling pathway may represent a potential novel therapeutic target for ICC treatment.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • BAP1 (BRCA1 Associated Protein 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule)
    |
    KRAS mutation • BAP1 mutation • CXCL12 expression • CXCL12 overexpression
    3ms
    HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. (PubMed, bioRxiv)
    CXCL9 + macrophages and dendritic cells and CXCL12-expressing stromal cells likely recruit CXCR3/CXCR4-expressing NK and T cells and CXCR7 + HLA-E HIGH tumor cells. NK and CD8 T cells remain functional within BCG-unresponsive tumors but are inhibited by HLA-E and PD-L1, providing a framework for combined NKG2A and PD-L1 blockade strategy for bladder-sparing treatment of BCG-unresponsive NMIBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • HLA-E (Major Histocompatibility Complex, Class I, E) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • ACKR3 (Atypical Chemokine Receptor 3) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    PD-L1 expression • IFNG expression • CXCL12 expression • CXCR4 expression
    3ms
    Concise review: breast cancer stems cells and their role in metastases. (PubMed, Ann Med Surg (Lond))
    Aberrantly expressed vascular cell adhesion molecule-1 (VCAM-1) that binds to collagen and elastin fibers on pulmonary parenchyma, and CXCR4 of BCSCs and CXCL12 in lung microenvironment may promote the cells homing and metastasis to lung. As in various types of BC metastases different markers that expressed by the cells and target organ microenvironment are responsible, BCSCs immunophenotyping can be used as target markers to predict the disease prognosis and treatment.
    Review • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD44 (CD44 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD24 (CD24 Molecule) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • NES (Nestin) • VCAM1 (Vascular Cell Adhesion Molecule 1) • PROM1 (Prominin 1)
    |
    CD44 expression • CXCL12 expression
    7ms
    Establishment of Early Blood Perfusion Promotes CXCL12 Expression and Recruits Monocytes/Macrophages in Damaged Adipose Tissue in Mice Model. (PubMed, Aesthetic Plast Surg)
    Established blood perfusion leads to up-regulation of CXCL12 during adipose tissue repair and regeneration, which may increase recruitment of monocytes to damaged adipose tissue. These findings increase understanding of the cellular events involved in fat graft survival after grafting.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • MRC1 (Mannose Receptor C-Type 1) • PLIN2 (Perilipin)
    |
    CXCL12 expression
    7ms
    Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma. (PubMed, Hepatol Int)
    The spatial distribution and density of TLSs revealing the characteristics of the cHCC-CCA immune microenvironment, significantly correlated with prognosis and provided a potential immunotherapy response biomarker for cHCC-CCA.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    7ms
    The effect of CXCL12 on survival outcomes of patients with viral hepatitis-associated hepatocellular carcinoma after hepatectomy. (PubMed, Heliyon)
    Our findings suggest that, when assessing the prognostic significance of CXCL12 in HCC, it is essential to consider the expression level of its receptor. Nevertheless, CXCL12 can potentially serve as a promising prognostic marker for HCC.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • ACKR3 (Atypical Chemokine Receptor 3)
    |
    CXCL12 expression • CXCL12-L • CXCR4 expression
    7ms
    Ethanolic extract of Euphorbia royleana Boiss. reduces metastasis of breast cancer cells and inhibits tumor progression in vivo. (PubMed, Med Oncol)
    Moreover, the GC-MS data revealed the presence of biologically active compounds (Lupeol, Phytol, phytosterol) and some rare (9, 19-Cyclolanost) phyto metabolites in ERA extract. However, further studies are suggestive to identify and isolate the therapeutic agents from ERA to combat BC and metastasis.
    Preclinical • Journal
    |
    CDH1 (Cadherin 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • MMP2 (Matrix metallopeptidase 2) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    CDH1 expression • CXCL12 expression
    7ms
    Inducible CXCL12/CXCR4-dependent extramedullary hematopoietic niches in the adrenal gland. (PubMed, Blood)
    Mirroring our findings in mice, we found reticular CXCL12+ cells co-expressing master niche-regulator FOXC1 in primary samples from human adrenal myelolipomas, a benign tumor composed of adipose and hematopoietic tissue. Our findings reignite long-standing questions regarding hormonal regulation of hematopoiesis and provide a novel model to facilitate the study of adult-specific inducible hematopoietic niches which may pave the way to therapeutic applications.
    Journal
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • FOXC1 (Forkhead Box C1)
    |
    CXCL12 expression
    8ms
    In vitro effects and mathematical modelling of CTCE-9908 (a chemokine receptor 4 antagonist) on melanoma cell survival. (PubMed, Clin Exp Pharmacol Physiol)
    CTCE-9908 significantly inhibited melanoma cell survival at a concentration 10 times lower than the IC50 in B16 F10 cells but not RAW 264.7 cells. However, CTCE-9908 did not affect CXCR4 phosphorylation, apoptosis, or cell cycle distribution in either cell line.
    Preclinical • Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • CASP3 (Caspase 3)
    |
    CXCL12 expression
    |
    PTX-9908
    8ms
    The CXCR4 might be a potential biomarker for esophageal squamous cell carcinoma: A meta-analysis. (PubMed, Medicine (Baltimore))
    CXCR4 might be a potential biomarker for the progress and prognosis evaluation, and therapeutic target for ESCC.
    Retrospective data • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression • CXCR4 expression
    9ms
    Liquid overlay and collagen-based 3D models for in vitro investigation of multiple myeloma. (PubMed, Tissue Eng Part C Methods)
    Additionally, the response of MM cells to bortezomib was substantially reduced in collagen, indicating the importance of 3D culture in the investigation of myeloma cell behavior, as drug-resistance is one of the most pertinent issues in cancer therapy. Impact statement: The application of 3D models in the investigation of multiple myeloma will provide better insight into their behaviour and drug resistance, allowing us to develop better treatment strategies. Here, we optimized a collagen-based approach which has shown to be reproducible, cost-effective and already providing an altered feedback in therapy response.
    Preclinical • Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    |
    bortezomib
    9ms
    Metadherin promotes stem cell phenotypes and correlated with immune infiltration in hepatocellular carcinoma. (PubMed, World J Gastroenterol)
    High levels of MTDH expression in patients with HCC are associated with poor prognosis, promoting tumor stemness, immune infiltration, and HCC progression.
    Journal
    |
    CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD4 (CD4 Molecule) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • MTDH (Metadherin)
    |
    CD133 expression • CXCL12 expression
    9ms
    Intratumoral CXCR4hi neutrophils display ferroptotic and immunosuppressive signatures in hepatoblastoma. (PubMed, Front Immunol)
    Moreover, our study pinpointed that infiltrated CXCR4hi neutrophils, regardless of their differential distribution of cell maturation status in HB tumor and para-tumor regions, were the genuine perpetrators for immune suppression. Our data characterized the ferroptosis-dependent immunosuppression energized by intratumoral CXCR4 expression neutrophils and suggest a potential cell target for cancer immunotherapies.
    Journal • IO biomarker
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression • CXCR4 expression
    10ms
    A landscape of patient-derived cancer-associated fibroblast signals in endometrial cancers. (PubMed, Am J Cancer Res)
    We demonstrate that endometrial CAFs can be cultured in an enzymatic-digestion-independent manner, and their signaling landscape can be mapped toward understanding CAF-TME dialogue. Our data will help unearth the functional relevance of endometrial CAFs in the context of clinical outcomes and designing CAF-inclusive therapy in the future.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin) • FAP (Fibroblast activation protein, alpha) • PVR (PVR Cell Adhesion Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • THY1 (Thy-1 membrane glycoprotein) • MMP1 (Matrix metallopeptidase 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • S100A4 (S100 calcium binding protein A4)
    |
    CD8 positive • CD44 expression • CXCL12 expression • VIM expression • EPCAM expression
    10ms
    Tumor-associated macrophages promoting PD-L1 expression in infiltrating B cells through the CXCL12/CXCR4 axis in human hepatocellular carcinoma. (PubMed, Am J Cancer Res)
    At last, we confirmed the communications among CAFs, Macrophages and B cells and their tumor-promoting effects by using an orthotopic mouse model of HCC. Immunosuppressive HCC TME involving cell-to-cell communications comprised MIF-secreting CAFs, CXCL12-secreting TAMs, and PD-L1-producing Bregs, and their regulation could be promising therapeutic targets in future immunotherapy for human HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD74 (CD74 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • MIF (Macrophage Migration Inhibitory Factor) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • CXCL12 expression • CXCR4 expression
    10ms
    Esketamine inhibits the JNK-c-Jun pathway in the spinal dorsal horn to relieve bone cancer pain in rats. (PubMed, Mol Pain)
    Intrathecal injection of the CXCR4 inhibitor AMD3100 reduced JNK and c-Jun phosphorylations, and intrathecal injection of the JNK inhibitor SP600125 and esketamine also alleviated TCI-induced pain and reduced the expression of p-JNK and p-c-Jun in microglia. Overall, our data suggest that the CXCL12/CXCR4-JNK-c-Jun signaling pathway of microglia in the spinal cord mediates neuronal sensitization and pain hypersensitivity in cancer-induced bone pain and that esketamine exerts its analgesic effect by inhibiting the JNK-c-Jun pathway.
    Preclinical • Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    |
    SP600125 • plerixafor
    11ms
    Interplay between androgen and CXCR4 chemokine signaling in myelin repair. (PubMed, Acta Neuropathol Commun)
    Depriving males of their testosterone or pharmacological inhibition of CXCR4, with the selective antagonist AMD3100, prevented the appearance of astrocytes expressing CXCR4, CXCL12 and AR within the demyelinated area and the concomitant recruitment of myelin forming oligodendrocytes...In patients with progressive MS, astrocytes expressing CXCR4 and AR surrounded myelin lesions, and their presence opposed the incursion of Schwann cells. These results highlight a mechanism of promyelinating testosterone signaling and the importance of normalizing its levels in combined myelin repair therapies.
    Journal
    |
    AR (Androgen receptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCR4 mutation • CXCL12 expression • CXCR4 expression
    |
    plerixafor
    11ms
    Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma. (PubMed, Int J Oral Sci)
    The secretion of CXCL12 recruits regulatory T cells (Tregs), leading to Treg infiltration and increased TGF-β secretion in the microenvironment and promotes the formation of a tumor immunosuppressive microenvironment. This study delineates the coordinate work axis of epithelial cells-iCAFs-Tregs in OSCC using SC, ST and TCGA bulk data, and highlights potential targets for therapy.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    CXCL12 expression • HIF1A expression
    11ms
    CXC chemokines: Potential biomarker and immunotherapeutic target for uterine corpus endometrial carcinoma. (PubMed, PLoS One)
    Heatmaps of DNA methylation of CXCL2/12/14/17 were investigated, and 4 CpGs of CXCL2, 16 CpGs of CXCL12, 3 CpGs of CXCL14/17 were identified where altered methylation affected the prognosis of UCEC patients. These findings provided novel insights into the immunologic features of UCEC and might pave the way toward the prognostic evaluation and immunotherapy selection based on CXCL2/12/14/17 expression status.
    Journal • IO biomarker
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL14 (C-X-C Motif Chemokine Ligand 14)
    |
    CXCL12 expression
    11ms
    Unveiling clinical significance and tumor immune landscape of CXCL12 in bladder cancer: Insights from multiple omics analysis. (PubMed, Chin J Cancer Res)
    Notably, CXCL12 expression emerged as a potential predictor of immunotherapy response and chemotherapy drug sensitivity in BCa patients. Taken together, these findings suggest aberrant production of CXCL12 in BCa tissues, potentially influencing the treatment responses of affected individuals.
    Journal • IO biomarker
    |
    CD163 (CD163 Molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    11ms
    Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian cancer. (PubMed, Commun Biol)
    Dual IHC staining show that tumor infiltrating CD8 T cells localize in proximity of CXCL12+ tumor area. Moreover, CXCL12 and/or CXCR4 antibodies confirm the immunosuppressive role of CXCL12-CXCR4 in high-stromal tumors.
    Journal • Stroma
    |
    CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CD8 overexpression • CD8 expression • CXCL12 expression
    1year
    Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma. (PubMed, Cancer Biomark)
    mRNA expression of TROP-2, SPL-2, and CXCL12 among PTC cases increased in larger tumor size, tumor stages III and IV, and LN metastasis. Moreover, there was an increase in CXCL-12 gene expression among PTC cases with extra-thyroid extension. Thus, TROP-2, SPL-2, and CXCL12 expressions could be possible diagnostic and prognostic markers in PTC.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    1year
    SPI1-mediated CXCL12 expression in bladder cancer affects the recruitment of tumor-associated macrophages. (PubMed, Mol Carcinog)
    Collectively, these findings suggest that SPI1 is involved in modulating TAM recruitment, representing a new mechanism through which it may influence tumor growth. This may be partly mediated by regulating CXCL12 expression.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • SPI1 (Spi-1 Proto-Oncogene) • MMP9 (Matrix metallopeptidase 9)
    |
    CXCL12 elevation • CXCL12 expression
    1year
    High density of CXCL12-positive immune cell infiltration predicts chemosensitivity and recurrence-free survival in ovarian carcinoma. (PubMed, J Cancer Res Clin Oncol)
    A high density of CXCL12 + TICs predicts a good response to chemotherapy, leading to a better overall survival and a longer recurrence-free interval. Moreover, with concomitant high CXCL12/CD66b TIC density, it is an independent favorable predictor of recurrence-free survival in patients with ovarian carcinoma.
    Journal • Immune cell
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • CEACAM8 (CEA Cell Adhesion Molecule 8)
    |
    CXCL12 expression
    1year
    TMI-Based Dose-Escalated Bone Marrow Transplantation Can Help Preserve the Bone Marrow Microenvironment and Reduce Cellular Senescence in Old Mice (ASH 2023)
    TMI-based dose escalates with young donor BMT in aged mice preserved BM microenvironment and reduced senescence of organs while TBI treatment causes senescence of the organs. Young donor BMT, which combined with TMI or TBI treatment, preserved bone structure and reduced senescence of HSPC and MSC. However, TMI treatment decreased the SA-β-gal staining and p16 expression significantly in organs such as the liver and gut, but not by TBI treatment.
    Preclinical
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CXCL12 expression
    1year
    Vascular Cell Adhesion Molecule-1 Regulates Bone Marrow Mesenchymal Stem Cell Maintenance and Niche Function (ASH 2023)
    Using a mouse model in which Vcam1 can be conditionally deleted in BM MSCs by a tamoxifen-inducible N-Cadherin-CreER line (referred to as Vcam1N-CadCreER), we found that deletion of Vcam1 significantly reduces the number (4-fold, p=0.0030), frequency (4-fold, p=0.0042), and viability (2-fold, p=0.0039) of BM MSCs...Interestingly, our scRNAseq analysis revealed increased expression of Cxcl12 and Scf in specific vascular and stromal cell populations, supporting the notion of HSC niche compensation. Overall, these findings demonstrate that MSC-derived Vcam1 is critical for BM MSC survival and their HSC niche function.
    Clinical
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TFRC • CDH2 (Cadherin 2) • VCAM1 (Vascular Cell Adhesion Molecule 1)
    |
    CXCL12 expression
    |
    tamoxifen
    1year
    Investigating novel biomarkers in uterine corpus endometrial carcinoma: in silico analysis and clinical specimens validation via RT-qPCR and immunohistochemistry. (PubMed, Am J Cancer Res)
    In addition, various additional aspects of the CCL25, CXCL10, CXCL12, and CXCL16 have also been uncovered in UCEC during the present study. Our findings offer novel insights that contribute to the clinical utility of CCL25, CXCL10, CXCL12, and CXCL16 chemokines as potential diagnostic and prognostic biomarkers in UCEC.
    Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL16 (C-X-C Motif Chemokine Ligand 16)
    |
    CXCL12 expression • CXCL10 expression
    1year
    ABCF1/CXCL12/CXCR4 Enhances Glioblastoma Cell Proliferation, Migration, and Invasion by Activating the PI3K/AKT Signal Pathway. (PubMed, Dev Neurosci)
    Furthermore, p-PI3K and p-AKT protein levels were downregulated by ABCF1 knockdown or CXCR4 blockade, which were prompted by ABCF1 overexpression or CXCL12 supplement. The ABCF1-CXCL12-CXCR4 axis was identified as a key player in GBM cell survival and metastasis by activating the PI3K/AKT signaling pathway in GBM cells.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression • CXCR4 expression
    1year
    Collagen content and C-X-C motif chemokine ligand 12 expression in neoplastic breast stroma. (PubMed, Rev Assoc Med Bras (1992))
    Low expression of C-X-C motif chemokine ligand 12 may be associated with a worse prognosis for breast cancer. Collagen staining analyzed using digital images represents an opportunity for clinical application and is indicative of the prognosis of the tumor microenvironment in breast carcinoma.
    Journal • Stroma
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression • CXCL8 expression
    over1year
    Comprehensive analysis of the role of CXCL family members in clear cell renal cell carcinoma. (PubMed, Curr Cancer Drug Targets)
    Conclusion In this study, we evaluated the expression levels of CXCL genes in KIRC and their prognostic potential in KIRC. CXCL-5,-9,-10,-11,-12, and -13 may be associated with ccRCC progression, and CXCL-1,-2,-5,-13, and -14 may be potential prognostic markers.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • CXCL14 (C-X-C Motif Chemokine Ligand 14)
    |
    CXCL12 expression
    over1year
    Integrative multi-omics analyses unravel the immunological implication and prognostic significance of CXCL12 in breast cancer. (PubMed, Front Immunol)
    The high-risk group patients were more sensitive to immunotherapy but resistant to docetaxel. CXCL12 has important immunological implication and prognostic significance in breast cancer. The CXCL12-related prognostic model could well predict the prognosis and treatment response of breast cancers.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • SDC1 (Syndecan 1) • GJA1 (Gap Junction Protein Alpha 1) • BMP8B (Bone Morphogenetic Protein 8b)
    |
    CXCL12 expression
    |
    docetaxel
    over1year
    The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. (PubMed, Pancreas)
    Serine racemase plays a prognostic role in PC and may be a potentially therapeutic target.
    Journal
    |
    CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression
    over1year
    Evaluation of the influence of the C-X-C motif chemokine ligand 12 / C-X-C chemokine receptor 4 axis on canine mammary gland tumor cell migration. (PubMed, J Vet Med Sci)
    This influence was canceled by pre-treatment with a CXCR4 antagonist. The results of our study suggest that the CXCL12/CXCR4 axis may be associated with the migration of canine MGT.
    Journal • Tumor cell
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CXCL12 expression • CXCR4 positive
    over1year
    MiR-30e-5p overexpression promotes proliferation and migration of colorectal cancer cells by activating the CXCL12 axis via downregulating PTEN (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    Overexpression of miR-30e-5p promotes the malignant behaviors of colorectal cancer cells by downregulating PTEN to activate the CXCL12 axis.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • MIR30E (MicroRNA 30e)
    |
    PTEN expression • CXCL12 expression • miR-30e expression
    over1year
    The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer (ESMO 2023)
    No significant results were obtained in any of the other subpopulations studied. Conclusions Patients diagnosed with advanced NSCLC with low expression of cytotoxic T lymphocytes in PB expressing CXCR4 show greater benefit from immunotherapy, due to greater tumor infiltration of lymphocytes receiving homing signals from the expression of CXCL12 in the tumor.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    CD8 expression • CXCL12 expression • CXCR4 expression
    over1year
    Tissue Expression And Prognostic Roles Of CXCL12 And CXCR4 In High-Grade Serous Ovarian Carcinoma (ESGO 2023)
    However, CXCR4 expression was not associated with survival outcomes.Conclusion CXCL12 expression level serves as a prognostic biomarker for HGSOC prognosis. Proteins related to the CXCL12-CXCR4 complex could be potential therapeutic targets for HGSOC treatment.
    BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    BRCA2 mutation • BRCA1 mutation • CXCL12 expression • CXCR4 expression
    over1year
    Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition. (PubMed, NPJ Precis Oncol)
    Anti-CD47 showed potent anti-tumor activity and synergized with PARPi in OC models. These data support clinical development of anti-CD47 therapy with PARPi in OC.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD47 (CD47 Molecule) • BRCA (Breast cancer early onset) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TGFB1 (Transforming Growth Factor Beta 1) • BRD4 (Bromodomain Containing 4) • SIRPA (Signal Regulatory Protein Alpha)
    |
    PD-L1 expression • CD47 overexpression • CD47 expression • CTLA4 expression • CXCL12 expression • CXCR4 expression • PD-L1 expression + CTLA4 expression
    over1year
    Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12. (PubMed, Front Immunol)
    Our findings suggest that serum cytokine CXCL12 levels can predict the outcomes of patients with NSCLC receiving ICI. Moreover, the combination of CXCL12 levels and PD-L1 status can predict outcomes with a significantly improved discriminatory power.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    PD-L1 expression • PD-L1 negative • CXCL12 expression